TIDMSBI
SourceBio International PLC
03 March 2021
RNS REACH
SourceBio International plc
("SourceBio", the "Company" or the "Group")
US expansion of COVID-19 testing services
COVID-19 testing services to be offered from San Diego
facilities
SourceBio International plc (AIM: SBI), the international
provider of integrated state-of-the-art laboratory services and
products , announces that its laboratory operations in San Diego,
California, are to be expanded to include COVID-19 qPCR testing
services.
The division based in the Torrey Pines Genomics hub of the US,
and home to prestigious as the Scripps Research Center, will mirror
that of the Company's set up in Nottingham, England, and is
expected to be fully operational in Q2 2021.
The Group's existing San Diego facility currently houses
Stability Storage Solutions and Genomics business units and the
enhanced space is planned to have the capacity to process up to
circa 5,000 samples per day with opportunities for continued
growth.
SourceBio already has cGMP, HPRA and FDA accredited facilitates
in the UK, Ireland and United States for a global client base. The
increased laboratory capacity of 1642 square feet will adhere to
requirements and be fully compliant with guidelines from the FDA.
The Company expects to receive the necessary accreditation to begin
processing samples within the planned timeframe.
The site will also benefit from the available local labour pool
which is rich in healthcare and research talent. The Company is to
employ additional staff onsite who will be needed to operate a 24/7
service. The laboratory will not only serve the local community but
also support SourceBio's global partners across the United
States.
Jay LeCoque, Executive Chairman, commented: "SourceBio has
already processed approaching 1,000,000 COVID-19 antigen RT-PCR
tests in the UK for the DHSC and the NHS, Private Hospital Groups
and Commercial customers since first offering its service in May
2020.
"This further investment in our San Diego facility increases our
overall capacity to increase COVID-19 qPCR testing services by up
to an additional 5,000 samples per day and means we can address the
clear market demand for COVID-19 testing in the US."
Contacts:
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07748
651 727
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products clients in the
healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis,
management, and care. Group revenues are derived from four core
businesses areas:
-- Infectious Disease Testing - a range of COVID-19 testing
services for Commercial enterprises, Private Healthcare groups, NHS
and the DHSC. Utilising multiple technologies (PCR, LAMPore, LAMP,
Lateral Flow, Quantitative Antibody tests and Whole Genome
Sequencing for positive results), SourceBio offers both screening
and gold standard COVID-19 testing and operates under ISO:15189
accreditation required by the DHSC. SourceBio also provides
employee testing solutions to industry, direct to consumer home
test kits (including 'Fit to Fly', 'Test to Release' and '2 & 8
Day International Travel' approved tests) whilst also being the
lead operator on Mobile Testing Unit services to support outbreak
testing for the DHSC, event and venue testing.
-- Healthcare Diagnostics - histopathology and clinical
diagnostic services for the NHS and private healthcare across the
UK and Ireland.
-- Genomics - DNA sequencing services for pharmaceutical and
biotechnology companies, academia, contract research organisations
(CROs) and other research groups in the UK, Europe and North
America.
-- Stability Storage - shelf-life testing services and equipment
for pharmaceutical and biotechnology companies, contract
manufacturers and analytical testing companies from around the
world but primarily in the UK, Ireland and the USA; and
More details on Group operations can be found here:
www.sourcebioscience.com
SourceBio International plc (SBI.L) is listed on the AIM market
of the London Stock Exchange.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAJTMBTMTMMTJB
(END) Dow Jones Newswires
March 03, 2021 02:00 ET (07:00 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Apr 2023 to Apr 2024
